Targeted Oncology
Keeping physicians up-to-date on the rapidly evolving field of targeted therapies and personalized medicine.
Prostate Cancer: Key Insights from AUA 2025
The Future of CAR T-Cell Therapy: Insights From ASCO GI and EHA/EBMT
Advances in Urologic Oncology and the Evolving Role of the Surgeon
Dr Burke Pinpoints Top Trends from ASH 2024
Controversy Over Adjuvant CDK4/6 Inhibitors in HER2-Negative Breast Cancer
Optimizing Hematologic Care With Real-World Data
Top Anticipations for ASH 2024: Oncologists Share Key Highlights to Watch
Initiating The Discussion on Informative Censoring in Clinical Trials
Expert Takeaway From WCLC Congress Involving Innovative Bispecific Antibody for NSCLC
AI Model (DeepHRD) Bests Standard Tests in Predicting HRD
The Impact of Weight-loss Treatments on Cancer in The US
Oncologists Share Breakthroughs From the 2024 World Conference on Lung Cancer
Emerging Experts: A Discussion With Tarantino on HER2-Low Breast Cancer and Antibody-Drug Conjugates
CRISPR Technology Explored in Oncology
AI Advances Enable Digital Twin as SOC Control in GVHD Clinical Trials
Navigating the Newly, Revealed World of MDS
Combining New Therapies and MRD Approaches Across Lymphomas
Comparing Afami-cel With Existing Treatments in Synovial Sarcoma
Should Frontline Myeloma Treatment Include a 3- or 4-Drug Regimen?
Immunotherapy Combinations Improve Survival in Advanced Renal Cell Carcinoma
Biomarker Testing Varies at Community/Academic Centers for Gastric Cancer
PSMA-Targeted Therapies in Clinical Development Show Promise for Prostate Cancer
Exploring the Reasons Why Certain Prostate Cancers Are More Aggressive
Clinical Trials Look at Promising Treatments in Mantle Cell Lymphoma
FDA-Approved Oral Hypomethylating Agent Regimen Excites MDS Landscape
ADAURA Study Demonstrates Promising Efficacy for Osimertinib in EGFR-Mutant NSCLC
Novel Agents Could Chemoimmunotherapy in Chronic Lymphocytic Leukemia
TRK Fusions Help to Fulfill Unmet Need in Thyroid Cancer Treatment Landscape
JAK Inhibitors Appear Hopeful for Transplant-Eligible MPN Patients in Retrospective Data
Selpercatinib Data Underscore Value of Precision Medicine in RET-Driven Lung Cancer